Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for amyotrophic lateral sclerosis
2017-004459-21Phase 2Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Nov 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Colchicine with Placebo (2 arms). Primary endpoint: Positive response based on ALSFRS-R at week 30. Started Nov 2018; status: completed.
02
Drugs
colchicine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2017-004459-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004459-21.